Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction
- 9 September 2010
- journal article
- research article
- Published by Wiley in World Journal of Surgery
- Vol. 34 (12) , 2821-2829
Abstract
Background Adenocarcinoma of the esophagogastric junction (AEG) as described by Siewert et al. is classified as one entity in the latest (7th Edition) American Joint Cancer Committee/International Union Against Cancer (AJCC/UICC) manual, compared with the previous mix of esophageal and gastric staging systems. The origin of AEG tumors, esophageal or gastric, and their biology remain controversial, particularly for AEG type II (cardia) tumors. Methods We adapted a large prospective database (n = 520: 180 type I, 182 type II, 158 type III) to compare AEG tumors under the new TNM system Pathological variables associated with prognosis were compared (pT, pN, stage, differentiation, R status, lymphovascular invasion, perineural involvement, number of positive nodes, percent of positive nodes, and tumor length), as well as overall survival. Results Compared with AEG type I tumors, type II and type III tumors had significantly (p < 0.05) more advanced pN stages, greater number and percentage of positive nodes, poorer differentiation, more radial margin involvement, and more perineural invasion. In AEG type I, 14/180 patients (8%) had >6 involved nodes (pN3), compared with 16 and 30% of patients classified type II and III, respectively. Median survival was significantly (p = 0.03) improved for type I patients (38 months) compared with those with tumors classified as type II (28 months) and type III (24 months). In multivariate analysis node positivity and pN staging but not AEG site had an impact on survival. Conclusions In this series AEG type I is associated with more favorable pathologic features and improved outcomes compared with AEG type II and III. This may reflect earlier diagnosis, but an alternative possibility, that type I may be a unique paradigm with more favorable biology, requires further study.Keywords
This publication has 23 references indexed in Scilit:
- Targeted HER2 Treatment in Advanced Gastric CancerOncology, 2010
- Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal CancerAnnals of Surgery, 2009
- The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trialsAnnals of Oncology, 2009
- The Number of Lymph Nodes Removed Predicts Survival in Esophageal Cancer: An International Study on the Impact of Extent of Surgical ResectionAnnals of Surgery, 2008
- Adenocarcinoma of the Esophagogastric Junction: Competition between Barrett and Gastric CancerJournal of the American College of Surgeons, 2007
- Adenocarcinoma of the Gastroesophageal JunctionAnnals of Surgery, 2007
- Immunopathological Patterns of the Stomach in Adenocarcinoma of the Esophagus, Cardia, and Gastric Antrum: Gastric Profiles in Siewert Type I and II TumorsThe Annals of Thoracic Surgery, 2007
- Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal CancerAnnals of Surgery, 2007
- Sentinel node biopsy to evaluate the metastatic dissemination of oesophageal adenocarcinomaBritish Journal of Surgery, 2004
- Review article: oesophago‐gastric adenocarcinoma — an epidemiological perspectiveAlimentary Pharmacology & Therapeutics, 2004